BioWorld

Feb. 28, 2005

Alteon Suspends Alagebrium Enrollment On Rat Toxicities

Alteon Inc. voluntarily suspended enrollment in its ongoing Phase II trials of alagebrium after preclinical data indicated high doses of the therapy could be associated with liver cell alterations and tumors. (BioWorld Today) Read More

Ecopia Raises C$9M, Plans IND Filing For Cancer Drug

Aggressive HIV Strain: Assay Possibilities, Case Study Limits

Bill On Stem Cells Referred To Subcommittee Of House

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...